Canopy Growth (CGC) Liabilities from Discontinued Operations (2022 - 2023)

Canopy Growth (CGC) reported Liabilities from Discontinued Operations of 13894446.86 for Q3 2023, up 449.72% sequentially from 2527542.48 in Q1 2023.

Canopy Growth (CGC) Liabilities from Discontinued Operations (2022 - 2023) Analysis & Trends

Canopy Growth (CGC) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 13894446.86 in Q3 2023.

For the quarter ending Q3 2023, Liabilities from Discontinued Operations changed N/A year-over-year to 13894446.86; the trailing twelve-month figure through Sep 2023 stood at 13894446.86 (changed N/A YoY), and the FY2023 full-year result was 2527542.48, changed N/A from the prior year.
Liabilities from Discontinued Operations rose to 13894446.86 in Q3 2023, from 2527542.48 in the prior quarter.
In the past five years, Liabilities from Discontinued Operations ranged from a high of 13894446.86 in Q3 2023 to a low of 2527542.48 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Canopy Growth	197.77 Mn	-68.15 Mn	-

Download Data